Our Article is Now Online in Pharmacological Reviews

Phragma Therapeutics
Phragma Therapeutics
  • Home
  • About
  • Our Programs
  • Contact
  • More
    • Home
    • About
    • Our Programs
    • Contact
  • Home
  • About
  • Our Programs
  • Contact
https://media.gettyimages.com/id/1159651600/video/cosmic-wormhole-tunnel-bacterium-future.jpg?b=1&s=640x640&k=20&c=-eYH2w-KdyB-X3l-RNSPte6KKq9JC_QOe0XJwz3YQPg=

Reshaping the Future of Brain Health by Targeting the Blood–Brain Barrier

Get in touch
The Opportunity

CNS diseases represent a large area of unmet need

Breakdown of the blood–brain barrier is increasingly recognized as a key driver of neuroinflammation, neuronal injury, and disease progression across multiple CNS disorders.


Yet NO approved therapies directly restore BBB integrity.


Phragma Therapeutics is building a platform designed to address this fundamental problem.

Find out more

Two Complementary Therapeutic Programs

Restoring the Blood–Brain Barrier

Restoring the Blood–Brain Barrier

Restoring the Blood–Brain Barrier

Our lead program focuses on correcting brain endothelial dysfunction and restoring BBB integrity.


This approach aims to rebalance the vascular and immune systems within the brain, reducing inflammation and protecting vulnerable neuronal populations.


Primary indication: Multiple Sclerosis


Additional potential indications include neurodegenerative and neuroinflammatory diseases.

Enabling CNS Drug Delivery

Restoring the Blood–Brain Barrier

Restoring the Blood–Brain Barrier

Most therapeutics cannot cross the blood–brain barrier, limiting the ability to treat diseases of the central nervous system.


Phragma is developing monoclonal antibodies that transiently and safely open the BBB, enabling delivery of biologics, RNA therapeutics, and gene therapies to the brain.


This platform could unlock treatment possibilities across a wide range of CNS diseases.

A Differentiated Scientific Platform

Our approach combines advances in endothelial biology, human BBB models, and translational biomarker platforms to enable efficient development of BBB-targeted therapies.


Key components include:

  • Human-centric BBB experimental models
  • Imaging
  • Cerebrospinal fluid biomarkers of barrier dysfunction

Together, these tools support early proof-of-concept and reduced translational risk.

Read more here

Our Partners

  • Home
  • About
  • Our Programs

Phragma Therapeutics Inc.

134 Coolidge Ave, Watertown, MA 02472, USA

Copyright © 2026 Phragma Therapeutics - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept